Pages that link to "Q41881124"
Jump to navigation
Jump to search
The following pages link to Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis (Q41881124):
Displaying 50 items.
- Medical treatments in the short term management of reflux oesophagitis (Q24234225) (← links)
- Medical treatments in the short term management of reflux oesophagitis (Q24245220) (← links)
- Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. (Q33624127) (← links)
- Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods (Q33698844) (← links)
- Overview of medical therapy for gastroesophageal reflux disease (Q33850185) (← links)
- Economic evaluation of long-term management strategies for erosive oesophagitis (Q33867824) (← links)
- pH, healing rate, and symptom relief in patients with GERD. (Q33898648) (← links)
- A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole (Q34174536) (← links)
- Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism (Q34345774) (← links)
- Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism (Q34346434) (← links)
- Influence of acid secretory status on absorption of omeprazole from enteric coated granules (Q34358008) (← links)
- Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine (Q34392389) (← links)
- Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring (Q34392553) (← links)
- Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers (Q34398323) (← links)
- Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects (Q34398436) (← links)
- Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders (Q34475730) (← links)
- Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients (Q34531831) (← links)
- The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease (Q34541695) (← links)
- Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders (Q34863257) (← links)
- Clinical pharmacology of omeprazole (Q34617917) (← links)
- What is heartburn worth? A cost-utility analysis of management strategies (Q34745082) (← links)
- A rational approach to uninvestigated dyspepsia in primary care: review of the literature (Q35037626) (← links)
- Whither surgery in the treatment of gastroesophageal reflux disease (GERD)? (Q35161878) (← links)
- Noncardiac chest pain: evaluation and treatment (Q35176967) (← links)
- Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease (Q35250682) (← links)
- Maintenance therapy: is there still a place for antireflux surgery? (Q35252692) (← links)
- Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion (Q35364870) (← links)
- A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials (Q35745058) (← links)
- The Indications, Applications, and Risks of Proton Pump Inhibitors (Q36091187) (← links)
- Current diagnosis and treatment of gastroesophageal reflux disease (Q36737716) (← links)
- Comparative role of omeprazole in the treatment of gastroesophageal reflux disease (Q36803997) (← links)
- Omeprazole drug interaction studies (Q36890310) (← links)
- Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial (Q36894058) (← links)
- Recent Advances in the Management of Gastro-Oesophageal Reflux Disease (Q36924121) (← links)
- The knife or the pill in the long-term treatment of gastroesophageal reflux disease? (Q36987502) (← links)
- Scleroderma esophagus (Q38020677) (← links)
- Histamine-2-receptor antagonists in gastro-oesophageal reflux (Q38367261) (← links)
- Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases (Q38672468) (← links)
- Treatment of peptic ulcer disease in the arthritic patient (Q38709591) (← links)
- Deprescribing versus continuation of chronic proton pump inhibitor use in adults. (Q38903118) (← links)
- On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial (Q39438205) (← links)
- Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta‐analysis of long‐term omeprazole trials (Q39455270) (← links)
- Proton pump inhibitory therapy: then and now. (Q39466750) (← links)
- Pharmacological Management of Gastro-Oesophageal Reflux Disease (Q39475567) (← links)
- Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis (Q39489396) (← links)
- Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study (Q39504404) (← links)
- Omeprazole (Q39524646) (← links)
- Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis (Q39535421) (← links)
- Therapeutic progress--review XXXIII. Are we making progress in the drug treatment of oesophageal disease? (Q39567824) (← links)
- Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis (Q41560226) (← links)